Abstract Library

#4090 Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,

#3843 VIPoma presenting as chronic diarrhea in a 30-year-old Filipino female

Introduction: Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. They can secrete a variety of peptide hormones including insulin, gastrin, glucagon, and vasoactive intestinal peptide. Secretory tumors such as vasoactive intestinal polypeptides are rare neuroendocrine pancreatic neoplasms characterized by watery diarrhea, hypokalemia, and hypochlorhydria.

Conference:

Presenting Author: Edejer P

Authors: Edejer P, Mendoza R, Pascasio C, Lin T, Cornelio G,

Keywords: Pancreatic NET, Octreotide, DOTATATE, diarrhea,

#3567 Metastatic mixed VIPoma/PPoma-induced diarrhoea causing renal failure

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare, but despite better prognosis than other pancreatic tumors, their presentation is often occult. VIPomas are a further subtype secreting vasoactive intestinal peptide (VIP). Associated symptoms are particularly non-specific, with watery diarrhoea and electrolyte disturbance which mimics less sinister pathology. Consequently, this presentation is often overlooked resulting in tumor progression and delayed diagnosis, hindering effective management.

Conference:

Presenting Author: Monaghan A

Authors: Monaghan A, Brown G, Takhar A,

Keywords: Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumor, pNET, Vasoactive Intestinal Peptide, VIPoma, Pancreatic Polypeptide,

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide

Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Marques B

Authors: Marques B, Martins R, Ribeiro J, Couto J, Ferrão H,

Keywords: vipoma, neuroendocrine, lanreotide, capecitabine, temozolamide,